# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

---

# FORM 6-K

---

**REPORT OF FOREIGN PRIVATE ISSUER**
**PURSUANT TO RULE 13a-16 OR 15d-16**
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of August 2021**

**Commission File Number: 001-40618**

---

# Stevanato Group S.p.A.
**(Translation of registrant's name into English)**

---

**Via Molinella 17**
**35017 Piombino Dese – Padua**
**Italy**
**(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☒

## EXHIBIT INDEX

The following exhibits are furnished as part of this Form 6-K:

| Exhibit | Description |
| --- | --- |
| 99.1 | Registrant's presentation for the investor conference call held on August 19, 2021 |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Stevanato Group S.p.A.**

| | | |
|---|---|---|
| Date: August 19, 2021 | By: | /s/ Franco Moro |
| | Name: | Franco Moro |
| | Title: | Chief Executive Officer and Chief Operating Officer |

Exhibit 99.1

Stevanato Group

# Second Quarter 2021 Financial Results

August 19, 2021

# Safe-Harbor Statement

**Forward-Looking Statements**
This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect", "foreseeable", "expected", "to be", "includes", "estimated", "assumes", "would provide", and other similar terminology. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: our future financial performance, including our revenue, operating expenses, and our ability to maintain profitability and operational and commercial capabilities; our expectations regarding the development of our industry and the competitive environment in which we operate; and our goals and strategies. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements : (i) our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation; (ii) we must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors to remain competitive; (iii) our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog; (iv) if we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected; (v) we are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth; (vi) our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers; (vii) our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs; (viii) significant interruptions in our operations could harm our business, financial condition and results of operations; (ix) our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows; and (x) our business may be harmed if our customers discontinue or spend less on research, development, production or other scientific endeavors; (xi) we may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors. This list is not exhaustive.

These forward-looking statements speak only as at their dates. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, the Company cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements. This press release also contains certain estimates regarding the Company's future prospects and performance, including, but not limited to, future revenues and earnings per share, capital deployment. All such statements and projections are based upon current expectations of the Company and involve a number of business risks and uncertainties. The Company disclaimers any current intention to update such guidance, except as required by law.

For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Part II, Item 1A. entitled "Risk Factors" in the Company's Quarterly Report on Form 6-K for the quarterly period ended June 30, 2021 and "Risk Factors" in our registration statement on Form F-1, dated July 16, 2021 and which was filed with the U.S. Securities and Exchange Commission in accordance with Rule 424(b) of the Securities Act of 1933, as amended, on July 16, 2021.

**Non-GAAP Financial Information**

This presentation contains non-GAAP measures. Please refer to the tables included in this Q2 2021 Earnings Press Release for a reconciliation of non-GAAP measures.

Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX, Adjusted Diluted EPS, Net Debt, and Free Cash Flow. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.

# Stevanato Group Second Quarter 2021 Earnings Call - Speakers

Franco Stevanato

Executive Board Chairman

Franco Moro

CEO

Marco Dal Lago

CFO

Lisa Miles

SVP IR

Mauro Stocchi

CBO

Paolo Patri

CTO

# First Half 2021 Highlights

**Mission-critical containment, delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries**

## STRONG 1H 2021 RESULTS; CONSISTENT PERFORMANCE

**€397M** 1H21 Revenue

**33%** YoY Revenue Growth

**€739M** Q2 2021 Backlog

**€108M** 1H21 Adj. EBITDA*

**58%** YoY 1H21 Adj. EBITDA Growth

**27%** 1H21 Adj. EBITDA Margin*

## PARTNER OF CHOICE

**700+** Customers in 2020

**97%**[1] Customer Retention

**41** of the top 50 pharma companies

**15** of the top 20 biotech companies

**100+** Total biotech customers

## MARKET LEADER

**#1** SG EZ-fill® pre-sterilized vial market share

**#1** Pen cartridge market share

**#2** Pre-fillable syringe market share

## GLOBAL SCALE

**70+** Years of operational excellence

**~4,400** Employees as of June 30, 2021

**16** Worldwide production & commercial sites

**70+** Countries served

*Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Please refer to slides 16-20 under the in this presentation for a Reconciliation of Non-GAAP measures

(1) Represents retention over the last ten years

## Creating and Driving Long-Term Shareholder Value




**Stevanato Group remains at the heart of the pharmaceutical value chain now and for decades to come**

### OUR MISSION

To deliver patient-centric solutions in support of our customers' needs to meet increasing market demand driven by a positive macro environment. Well positioned to grow profitably and capture market share over the next several years.

### INVEST PROCEEDS FROM IPO TO DRIVE SUSTAINABLE, LONG-TERM ORGANIC GROWTH

1) Geographic expansion
2) Research and development to sustain and accelerate our High Value Solutions (HVS)
3) Selective and disciplined M&A

# Q2 2021 Operating and Financial Results Highlights

- Delivered solid YoY Q2 operating and financial results highlighted by double digit revenue growth
- Steady progress in strategic transition of revenue mix toward HVS – now contributing 24% of revenues
- HVS advantages for customers
  - Reduced time to market
  - Lower total cost of ownership
  - Increased quality, and
  - Improved flexibility (including risk mitigation)
- Strong Q2 FY21 order intake of €278 million
- Total backlog of €739 million
- The Company estimates that it has visibility of approximately 94% of full year forecasted revenue for fiscal 2021, comprised of first half 2021 revenue contributions plus currently estimated backlog for the second half.

| Q2 2021 RESULTS; OPERATIONAL AND FINANCIAL PERFORMANCE | | |
|---|---|---|
| **€204.0M**<br>Q2 21 Revenue | **26%**<br>YoY Revenue Growth | **€0.14**<br>Diluted EPS |
| **€52.4M**<br>Q2 21 Adj. EBITDA* | **30%**<br>YoY Adj. EBITDA Growth | **25.7%**<br>Q2 21 Adj. EBITDA Margin* |

*Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Please refer to slides 16-20 under the in this presentation for a Reconciliation of Non-GAAP measures

# Investment Approach: Proven Track Record of Optimizing CAPEX

## Expansion Initiatives in Italy and Abroad Since 2016 Have Yielded Double-Digit Annual Growth that Continues Today

- Served as the catalyst to meet the significant increase in demand precipitated by COVID
- Allowed significant increase in production in other core products outside of the vaccine space, including our HVS in higher-margin products such as pre-sterilized vials, cartridges, and syringes
- **… and allowed us to remain number one in the insulin pen cartridge market**

**CASE STUDY: €220 MILLION CAPEX INVESTMENT IN EZ-FILL® EXPANSION (2016-2021)**

- **Key metrics and capacity increases:**
  - EZ-Fill® pre-fillable sterile syringes: production output to double from 2016 vs 2021, expected to triple by 2023.
  - EZ-Fill® sterile vials and cartridges: production output increased 11X from 2016 to 2021, expected to be 19X by 2023.

***Made timely investments in capacity to enable us to stay ahead of customers' rising demand for our HVS. Intend to replicate this investment strategy in the years ahead***

# Investing to Expand Capacity

**Investments in the Fastest Growing U.S. and China Markets Intended to Advance our Position with Customers Across the Pharmaceutical, Biotech, and Life Sciences Industries**

- Planned CapEx spend of ~€300 million in the U.S. and China to expand existing footprint and enhance our proximity to customers in attractive end markets

UNITED STATES

**Well-positioned to become a larger player in the sophisticated and rapidly growing biologics market**

- Expect to break ground in Indiana in the Fall of 2021
- ~18 months of construction, followed by startup and customer validation expected in 2023
- Currently targeting revenue generation expected to begin around the end of 2023 or early 2024

CHINA

**Predominance of biosimilars, emerging biologics market**

- Goal is to take advantage of market timing to be among first movers
- Estimate construction in Zhangjiagang expected to start in early 2022 with revenue generation expected in 2H 2024.

BOOSTING EFFORTS IN RESEARCH AND DEVELOPMENT

**Emphasis on service capabilities**

- Our Technology Excellence Centers in Boston and Italy help us gain an early entry point with customers, expand our presence in the biologic drug pipeline, and expand our portfolio of proprietary solutions across all product lines

# Current Macro Trends Generate Favorable Tailwinds for Decades to Come

**Need to address major challenges, including:**

- Aging populations
- Increasing complexity in health conditions and comorbidity rates
- Significant shift in patients seeking to manage their conditions and access care closer to their home environment

**We believe we are uniquely well-positioned to capitalize on trends**

**Our priority is to support our customers in creating and delivering the patient-centric solutions, which is central to our philosophy and vison**

# Financial Overview: Q2 2021 Revenue




*Revenue growth calculated on a constant currency basis was 28.5%




Q2 2021:
Ex-Covid:
Achieved double-digit growth

| ESTIMATED COVID GROSS REVENUE | |
|---|---|
| Q2 2021 | ~15% |
| FY 2021E | ~13% to ~17 % |

*For a reconciliation from revenue to constant currency revenue, please refer to slides 16-20 under the in this presentation

# Financial Overview: Q2 2021 Accelerating Momentum Across Our Business

- Gross margin improvement due to focus on high value solutions
- Adjusted operating profit margin* and Adjusted EBITDA* growth due to gross margin expansion and efficient cost management
- Parallel continued investment in R&D activities to sustain and accelerate the pipeline of high value solutions

**GROSS MARGIN**

Gross margins improved 100 bps




**ADJUSTED OPERATING PROFIT MARGIN***

Adjusted operating profit margin improved 240 bps




**ADJUSTED EBITDA MARGIN***

Adjusted EBITDA margin improved 90 bps




*Adjusted operating margin and Adjusted EBITDA margin are non-GAAP measures. Please refer to slides 16-20 under the in this presentation for a Reconciliation of Non-GAAP measures

# Financial Overview Continued: Q2 2021

### Diluted EPS and Adjusted Diluted EPS

Q2 2021 Operating profit and EBITDA included €8.6 million one-time benefit (€4.4 million of net profit, or €0.02 per diluted EPS)

Q2 2021 Diluted EPS of €0.14 and Adjust diluted EPS of €0.12

### Segment Overview

BIOPHARMACEUTICAL AND DIAGNOSTIC SEGMENT (BDS)

- 23% YoY growth (despite unfavorable fx translation)
- Benefited from +27% revenue increase in high value solutions and 21% increase in other containment and delivery solutions versus Q2 2020

ENGINEERING SEGMENT

- 50% YoY growth across all business lines (Q2 2021 revenue from third parties of €29.1 million)
- Margin expansion driven by increase in after-sales customer support activities and improved manufacturing network synergies.

BDS & ENGINEERING SEGMENT PERFORMANCE REVENUE (In € millions)



## Balance Sheet, Cash Flow and Capital Allocation

**Strong liquidity:** mix of cash from operations, debt facility capacity and proceeds are ample to address future liquidity needs

**Capital Allocation Priorities**

1. Expand capacity in HVS where demand is high
2. Investments in research and development to maintain and accelerate HVS pipeline
3. Explore selective M&A opportunities that complement our existing book of business and accelerate our growth plan

| Q2 2021 | | |
|---|---|---|
| €54.1M | €23.7M | €31.3M |
| Cash from Operations | Capital Expenditures | Free Cash Flow* |

| JUNE 30, 2021 | |
|---|---|
| €100.8M | 1x |
| Total Cash and Cash Equivalents | Net Debt[2]/LTM EBTIDA* |

[2] Net debt is defined as current and non-current financial liabilities, minus other current financial assets, financial receivables, and cash and cash equivalents

*Free Cash Flow and EBITDA are non-GAAP measures. Please refer to slides 16-20 under the in this presentation for a Reconciliation of Non-GAAP measures

# Initiating 2021 Guidance

| Establishing 2021 Guidance | | | |
|---|---|---|---|
| **€820M - €830M** | **€0.43 - €0.47** | **~252.7M** | **€212M - €217M** |
| Revenue | Adj. Diluted EPS* | Weighted Average Shares Outstanding | Adj. EBITDA* |

*Adjusted EBITDA and Adjusted Diluted EPS are non-GAAP measures. Please refer to slides 16-20 under the in this presentation for a Reconciliation of Non-GAAP measures

**Notes to Non-GAAP Financial Measures:**
This presentation contains non-GAAP measures.

Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX, Adjusted Diluted EPS, Net Debt, and Free Cash Flow. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.

A reconciliation of these adjusted Non-GAAP financial measures to the comparable GAAP financial measures is included in the accompanying tables.

# Reconciliation of Non-GAAP Measures (Unaudited)

*Reconciliation of Net Debt and EBITDA*

**Reconciliation of Net Debt**
**(Amounts in € millions)**

| (Amounts in € millions) | As of June 30, 2021 | As of December 31, 2020 |
|---|---|---|
| Non-current financial liabilities | 264.6 | 294.1 |
| Current financial liabilities | 80.7 | 81.2 |
| Financial Receivables from associate [(1)] | (1.3) | (1.3) |
| Other current financial assets | (27.9) | (41.5) |
| Cash and cash equivalents | (100.8) | (115.6) |
| **Net Debt** | **215.2** | **216.9** |

[(1)] The Financial Receivable granted to the associate Swissfillon AG is included in line "Other non-current financial assets" of the Interim condensed consolidated statements of financial position.

**Reconciliation of EBITDA**

**(Amounts in € millions)**

**(Amounts in € millions, except as indicated otherwise)**

| | For the three months ended June, 30 | | Change | For the six months ended June, 30 | | Change |
|---|---|---|---|---|---|---|
| | 2021 | 2020 | % | 2021 | 2020 | % |
| Net Profit | 34.5 | 20.7 | 66.7 | 71.0 | 27.9 | 154.5 |
| Income Taxes | 13.4 | 7.1 | 88.7 | 18.6 | 10.6 | 75.5 |
| Finance Income | (2.3) | (3.8) | (39.5) | (4.3) | (9.5) | (54.7) |
| Finance Expenses | 2.4 | 3.4 | (29.4) | 5.6 | 13.6 | (58.8) |
| Share of Profit of an Associate | (0.4) | (0.2) | 100.0 | (0.4) | (0.2) | 100.0 |
| **Operating Profit** | **47.6** | **27.1** | **75.6** | **90.5** | **42.5** | **112.9** |
| Depreciation and Amortization | 13.4 | 13.1 | 2.3 | 26.4 | 25.7 | 2.7 |
| **EBITDA** | **61.0** | **40.2** | **51.7** | **116.9** | **68.2** | **71.4** |

# Reconciliation of Non-GAAP Measures (Unaudited)

*Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit and Diluted EPS*

| Three months ended June 30, 2021 | EBITDA | Operating Profit | Income Taxes | Net Profit | Diluted EPS |
|---|---|---|---|---|---|
| Reported | 61.0 | 47.6 | 13.4 | 34.5 | 0.14 |
| Adjusting items: | | | | | |
| Restructuring and related charges [2] | 0.7 | 0.7 | 0.2 | 0.5 | 0.00 |
| Incentive Plans Settlement [3] | (7.8) | (7.8) | (4.0) | (3.8) | (0.02) |
| IPO costs reversed (booked as at March, 31 2021)[4] | (1.5) | (1.5) | (0.4) | (1.1) | (0.00) |
| Adjusted | 52.4 | 39.0 | 9.2 | 30.1 | 0.12 |
| *Adjusted Margin* | *25.7%* | *19.1%* | | | |

| Six months ended June 30, 2021 | EBITDA | Operating Profit | Income Taxes | Net Profit | Diluted EPS |
|---|---|---|---|---|---|
| Reported | 116.9 | 90.5 | 18.6 | 71.0 | 0.29 |
| Adjusting items: | | | | | |
| Restructuring and related charges [2] | 1.0 | 1.0 | 0.3 | 0.7 | 0.00 |
| Incentive Plans Settlement [3] | (9.9) | (9.9) | (4.8) | (5.1) | (0.02) |
| Tax Incentive - Patent Box[5] | - | - | 5.5 | (5.5) | (0.02) |
| Adjusted | 108.0 | 81.6 | 19.6 | 61.1 | 0.25 |
| *Adjusted Margin* | *27.2%* | *20.6%* | | | |

| Three months ended June 30, 2020 | EBITDA | Operating Profit | Income Taxes | Net Profit | Diluted EPS |
|---|---|---|---|---|---|
| Reported | 40.2 | 27.1 | 7.1 | 20.7 | 0.09 |
| Adjusting items: | - | - | - | - | - |
| Adjusted | 40.2 | 27.1 | 7.1 | 20.7 | 0.09 |
| *Adjusted Margin* | *24.8%* | *16.7%* | | | |

| Six months ended June 30, 2020 | EBITDA | Operating Profit | Income Taxes | Net Profit | Diluted EPS |
|---|---|---|---|---|---|
| Reported | 68.2 | 42.5 | 10.6 | 27.9 | 0.12 |
| Adjusting items: | - | - | - | - | - |
| Adjusted | 68.2 | 42.5 | 10.6 | 27.9 | 0.12 |
| *Adjusted Margin* | *22.9%* | *14.2%* | | | |

(2) During the three and the six months ended June 30, 2021, the Group recorded € 0.7 million and € 1.0 million respectively in restructuring and related charges for the consolidation of Balda plants in the U.S.

(3) During the three and the six months ended June 30, 2021, the Group recorded € 7.8 million and € 9.9 million respectively, within general and administrative expenses, as accrual reversal related to the early termination of incentive plans aimed at a limited number of key managers.

(4) During the three months ended June 30, 2021, the Group reversed the IPO project costs prudentially accrued at P&L as of March 31, 2021.

(5) During the first quarter 2021, the Group reached an agreement with Italian Tax Agency regarding the so-called “Patent box regime”, resulting in a retroactive € 5.5 million tax saving for the financial years 2016-2020.

# Reconciliation of Non-GAAP Measures (Unaudited)

*Reconciliation of Constant Currency*

**Reconciliation of Revenue to Constant Currency Revenue [6]**
**(Amounts in € millions)**

| Three months ended June 30, 2021 | Biopharmaceutical and Diagnostic Solutions | Engineering |
|---|---|---|
| Reported Revenue | 174.9 | 29.1 |
| Effect of changes in currency translation rates | 4.0 | - |
| Constant Currency Revenue | 178.9 | 29.1 |

| Six months ended June 30, 2021 | Biopharmaceutical and Diagnostic Solutions | Engineering |
|---|---|---|
| Reported Revenue | 335.4 | 61.4 |
| Effect of changes in currency translation rates | 9.8 | (0.1) |
| Constant Currency Revenue | 345.2 | 61.3 |

[6] Constant currency revenue translates the current-period reported revenue of subsidiaries whose functional currency is other than the Euro at the applicable foreign exchange rates in effect during the comparable prior-year period.

In the second quarter 2021, revenue on a constant currency basis grew by 25.5% and by 50.2% in the Biopharmaceutical and Diagnostic Solutions segment and in the Engineering segment respectively. In the first half 2021, revenue on a constant currency basis grew by 31.3% and by 73.0% in the Biopharmaceutical and Diagnostic Solutions segment and in the Engineering segment respectively.

# Reconciliation of Non-GAAP Measures (Unaudited)

*Reconciliation of Free Cash Flow*

**Free Cash Flow (Unaudited)**
**(Amounts in € millions)**

| (Amounts in € millions) | For the three months ended June 30, | | For the six months ended June 30, | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| Cash Flow from Operating Activities | 54.1 | 53.9 | 60.0 | 44.6 |
| Interest paid | 1.1 | 1.3 | 2.3 | 2.4 |
| Interest received | (0.2) | (0.1) | (0.3) | (0.4) |
| Purchase of property, plant, and equipment | (22.3) | (17.3) | (44.1) | (41.4) |
| Purchase of intangible assets | (1.4) | (1.5) | (2.1) | (2.1) |
| **Free Cash Flow** | **31.3** | **36.3** | **15.8** | **3.1** |

# Reconciliation of Non-GAAP Measures (Unaudited)

*Reconciliation of Adjusted Guidance*

**Reconciliation of 2021 Guidance for Operating Profit, EBITDA, Adjusted EBITDA, Adjusted Net Profit and Adjusted Diluted (Unaudited)**
**(Amounts in € millions, except per share data)**

| | 2021 Guidance | | | | |
|---|---|---|---|---|---|
| | **Operating Profit** | **Depreciation and Amortization** | **EBITDA** | **Net Profit** | **Diluted EPS** |
| Reported | 155.5 – 160.5 | 58.5 | 214.0 – 219.0 | 113.0 – 122.8 | 0.45 – 0.49 |
| *Adjusting items* | | | | | |
| Restructuring and Related Charges | 1.6 | - | 1.6 | 1.1 | 0.00 |
| Incentive Plans Settlement | (9.9) | - | (9.9) | (5.1) | (0.02) |
| Tax Incentive – Patent Box | | - | | (5.5) | (0.02) |
| One-time Bonus to Employees | 6.5 | - | 6.5 | 4.9 | 0.02 |
| **Adjusted** | **153.5 – 158.5** | **58.5** | **212.0 – 217.0** | **109.0 - 118.8** | **0.43 – 0.47** |

Contacts:

**Media**
Stevanato Group
media@stevanatogroup.com

**Investor Relations**
Lisa Miles
Lisa.miles@stevanatogroup.com

Stevanato Group